Podcasts about Drug discovery

Dr. Matt Harlow, PhD, Senior Scientist at TRIANA Biomedicines, shares his path since Vanderbilt and his daily work life in drug discovery. 

Robert Abel, chief scientific officer at Schrödinger, says advanced computational tools are changing the pace and accuracy of drug discovery. In a recent episode of The Top Line podcast, Abel outlined three areas where AI and machine learning are making the greatest impact: understanding disease biology, predicting protein structures and designing drug molecules. Schrödinger’s platform uses physics-based simulations alongside AI to evaluate millions of molecules in days, compared with the thousands traditionally synthesized in a year. Abel pointed to real-world results, including a program that reached a clinical trial candidate in just 10 months — far faster than industry averages. He said the technology also helps overcome challenges such as improving drug selectivity and reducing the need for animal testing, aligning with FDA priorities. Abel will share more insights during his upcoming talk at AAPS PharmSci 360 in San Antonio this November. His session abstract is available here. To hear more about Schrödinger’s work in computational drug discovery, listen to the full interview.See omnystudio.com/listener for privacy information.

Welcome to the Olink® Proteomics in Proximity podcast!  Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  World Health Organization (2003). Adherence to long-term therapies: evidence for action (PDF). Geneva: World Health Organisation. ISBN 978-92-4-154599-0 Research articles and news·       Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Studyhttps://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientifics-Olink-Platform-Selected-for-Worlds-Largest-Human-Proteome-Study/default.aspx·       Hamilton Se-Hwee Oh et al 2025. Plasma proteomics links brain and immune system aging with healthspan and longevityhttps://www.nature.com/articles/s41591-025-03798-1. Nature Medicine (2025)·       Song, Y., Abuduaini, B., Yang, X. et al. Identification of inflammatory protein biomarkers for predicting the different subtype of adult with tuberculosis: an Olink proteomic study. Inflamm. Res. 74, 60 (2025). https://doi.org/10.1007/s00011-025-02020-9·       Ferhan Qureshi et al 2023. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics clinical application 2023·       Dhindsa, R.S., Burren, O.S., Sun, B.B. et al. Rare variant associations with plasma protein levels in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06547-xhttps://www.nature.com/articles/s41586-023-06547-x·       Sun, B.B., Chiou, J., Traylor, M. et al.  Plasma proteomic associations with genetics and health in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06592-6 https://www.nature.com/articles/s41586-023-06592-6 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac495/6676779·       Eldjarn GH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023 Oct;622(7982):348-358. doi: 10.1038/s41586-023-06563-xhttps://www.nature.com/articles/s41586-023-06563-x#Sec44·        Carrasco-Zanini et al 2024 Proteomic prediction of common and rare diseases. https://www.nature.com/articles/s41591-024-03142-z . NatureMedicine volume 30,  pages2489–2498 (2024)·       Watanabe K, Wilmanski T, Diener C, et al. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention.https://www.nature.com/articles/s41591-023-02248-0·       Petrera A, von Toerne C, Behlr J, et al. Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling. (2020) Journal of Proteome Research, https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00641·       Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens. Kardell O, von Toerne C, Merl-Pham J, König AC, Blindert M, Barth TK, Mergner J, Ludwig C, Tüshaus J, Eckert S, Müller SA, Breimann S, Giesbertz P, Bernhardt AM, Schweizer L, Albrecht V, Teupser D, Imhof A, Kuster B, Lichtenthaler SF, Mann M, Cox J, Hauck SM. J Proteome Res. 2024 Jan 5;23(1):117-129. doi: 10.1021/acs.jproteome.3c00473. Epub 2023 Nov 28. PMID: 38015820 https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00473·       Wei, S., Shen, R., Lu, X. et al. Integrative multi-omics investigation of sleep apnea: gut microbiome metabolomics, proteomics and phenome-wide association study. Nutr Metab (Lond) 22, 57 (2025). https://doi.org/10.1186/s12986-025-00925-0·       Liu, L., Li, M., Qin, Y. et al. Childhood obesity and insulin resistance is correlated with gut microbiome serum protein: an integrated metagenomic and proteomic analysis. Sci Rep 15, 21436 (2025). https://doi.org/10.1038/s41598-025-07357-z·       Zhang, Xiaotao et al.Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. eBioMedicine, Volume 98, 104873 (2023.).  10.1016/j.ebiom.2023.104873·      &nb...

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA's ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O'Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library 

Send us a textIn this episode of the Life Science Success Podcast my guest is Mark Stead, Head of Business Development at Atomic AI, a pioneering biotech company using artificial intelligence and structural biology to develop innovative RNA-targeted therapeutics. Mark brings over 12 years of experience in biotechnology, with a proven track record of negotiating high-value partnerships and driving strategic collaborations in drug discovery.00:00 Introduction to the Life Science Success Podcast00:30 Meet Mark Stead: Journey into Life Sciences03:26 Career Insights: From Amgen to Atomic AI11:20 Innovations at Atomic AI: Leveraging AI and Structural Biology19:37 The Future of AI in Drug Discovery31:03 Leadership and Personal Insights39:38 Conclusion and Farewell

For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/In this episode of the Pharmaron DMPK Insights Podcast Series, Simon Taylor and Dr. Emile Chen​ discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decision making from initial modality selection, through molecule optimization, translational science and clinical dosage planning. Simon and Emile discuss the concepts and practical applications of PKPD and explore the concept of model-based target pharmacology assessment in combination with physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) modelling to improve decision making.** Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery”, J Med Chem. 2021 Mar 25;64(6):3185-3196.​ We will address the following points:​ What is PKPD and its importance throughout a discovery project lifecycle​ How PKPD can be used to guide decision making including case study examples​ How a combination of physiologically based pharmacokinetic/ pharmacodynamic (PBPK/PD) modeling and machine learning (ML) can be used to elucidate the optimal combination of properties for the targeted pharmacology Our Moderator:Simon Taylor – Vice President, Drug Discovery at Pharmaron  Simon Taylor is Vice President of Drug Discovery and is based in Hoddesdon, UK. With over 27 years of industry experience, he is responsible for DMPK/ADME and PKPD strategy, including human extrapolation and PBPK modelling and simulation, for Pharmaron's integrated drug discovery projects from early discovery through to IND submission. Before Pharmaron, Simon worked at GSK for 20 years, leading DMPK and Quantitative Pharmacology teams and projects from the Hit Identification stage through to the clinic. He has worked across respiratory, inflammation, oncology, and cardiovascular therapy areas with drugs of varying routes of administration. Simon has a BSc in Pharmacology from the University of Leeds and an MSc in Model Based Drug Development from the University of Manchester. He has co-authored over 30 scientific publications in the literature.  Our Speakers:Dr. Emile Chen – Formerly Director, Modeling and Translational Biology at GlaxoSmithKline Dr. Emile Chen has thirty years of industrial experience divided between early discovery involved in lead optimization and candidate selection, and late-stage development, including authoring and reviewing of regulatory documentation and NDA submission. Until March 2024, he was in the System Modeling and Translational Biology group, using PBPK, Mechanistic PKPD modeling, QSP, and machine learning techniques to solve project questions and thereby enhance scientific productivity.  Emile received his undergraduate degree from the University of California, Los Angeles, and his PhD from Northwestern University in the field of Biomedical Engineering, specializing in the development of mathematical models for information processing in the brain. He began his pharmaceutical career at Hoffmann-La Roche in 1993, following a postdoctoral fellowship at the University of California, San Francisco. He joined GlaxoSmithKline in 1996. Over the years, he has led ADME and PK groups at various times, supporting both early discovery and late development DMPK efforts. More recently, rStay tuned for more podcasts in our Pharmaron DMPK Insights Series!

In this episode of Future Fuzz, we sit down with Darius Meadon, Chief Marketing Officer at OWKIN, one of Forbes and Sequoia Capital's top 50 AI companies. OWKIN is pioneering the use of agentic AI and multimodal data in healthcare to accelerate diagnostics and drug discovery. Darius shares how his team communicates complex science to biotech and pharma clients, why video content and personalization are crucial in modern B2B marketing, and what it takes to build long-term trust in the highly regulated world of healthcare innovation.From live demos that stop traffic at global conferences to AI-powered personalization strategies, Darius reveals the mindset and tools that drive engagement and growth in a challenging sector. This episode is a must-listen for marketers, healthcare innovators, and tech leaders aiming to scale with science.Guest BioDarius Meadon is the Chief Marketing Officer at OWKIN, an agentic AI company on a mission to decode complex biology and accelerate the development of life-saving treatments and diagnostics. OWKIN's work spans cutting-edge areas such as spatialomics, proteomics, and multimodal data fusion. Prior to OWKIN, Darius built a robust career in marketing, brand strategy, and innovation with global giants like GSK, Bayer, Unilever, and Coca-Cola.With a Master's in Science from Oxford and further studies at Harvard, Darius blends scientific depth with marketing expertise. He's a passionate advocate for science communication, video-led storytelling, and smart segmentation strategies to cut through in a complex, regulated B2B space.TakeawaysPersonalization must align message, format, and channel to buyer pain pointsVideo is essential: explainer content, product sizzles, and authentic team videos all build engagementIn-person events demand standout visuals, live demos, and smart giveawaysFounder-led content can drive authenticity and start bold conversationsAI-powered tools like LLMs enable real-time product demos that resonate deeply with usersLong sales cycles in pharma require a robust, multi-touch, 360-degree marketing approachLinkedIn newsletters outperform email for engagement in saturated inboxesChapters00:00 Welcome and Intro to Darius Meadon 01:00 The Origin Story of OWKIN 02:10 Using AI to Diagnose and Predict Cancer Outcomes 03:45 Breaking Down Biology Complexity for Drug Discovery 05:20 How to Simplify Science for Sophisticated Buyers 06:40 The Power of Video in B2B Healthcare Marketing 07:50 Smart Segmentation and Multi-Touch Engagement Strategy 09:00 Navigating Long Sales Cycles in Pharma 10:10 Creating Demand Before Product Launches 11:00 Founder-led Content and Balancing Authenticity with Brand 12:20 How OWKIN Uses LinkedIn to Scale Thought Leadership 15:00 Thoughts on Personalization and Agentic AI 20:00 Matching Buyer Pain Points with the Right Channel and Format 24:00 How OWKIN Stands Out at Large Conferences 26:00 From Plushies to Illustrated Booklets: Smart Giveaways that Stick 28:30 Closing Thoughts and Where to Connect with DariusLinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Darius Meadon on LinkedIn here : ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Justin Campbell on LinkedIn here :

In this cutting-edge episode, we explore how Edge AI is transforming drug discovery and revolutionising laboratory workflows, real-time molecular analysis, and protein folding predictions—all at the source of data collection. Joining us is Nuri Cankaya, Vice President of Commercial Marketing at Intel Corporation, and a renowned thought leader in AI and healthcare innovation.You'll discover how AI at the edge—enabled by on-device NPUs, GPUs, and CPUs—is unlocking privacy-preserving, high-performance computing in the most sensitive environments, such as clinical labs and pharmaceutical R&D centers. Nuri shares his deep experience in AI, discusses hardware configurations for edge deployments, and provides real-world examples of AI accelerating high-throughput screening, compound discovery, and target validation.Key Topics:What is Edge AI and how it differs from cloud-based AIHow real-time AI in the lab enables faster, cheaper drug discoveryHardware requirements: NPU, GPU, CPU integration for edge computingThe role of AlphaFold and protein folding prediction in therapeutic developmentUse cases in molecular screening, genomics, and clinical trial simulationsHow Edge AI preserves data privacy and complies with GDPR and HIPAAPredictions for AGI (Artificial General Intelligence) and Quantum Computing in healthcareStrategic advice for pharma leaders and biotech innovators looking to pilot AIThe energy efficiency and sustainability gains from Edge AI vs. cloud AIAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it's being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI's role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

We've long marveled at how efficiently plants convert sunlight into energy—but no one guessed they were using quantum mechanics to do it.In this episode, we speak with Greg Engel, a pioneering University of Chicago biophysicist who helped launch the field of quantum biology. Engel explains how plants and bacteria evolved to exploit quantum effects for photosynthesis—and how understanding these systems could spark a revolution in quantum sensing, medicine, and neuroscience.Engel's team has already built quantum sensors inspired by nature's designs, with the potential to transform how we detect disease, develop drugs, and even read neural signals. The ultimate goal? A new era of quantum medicine, powered by the weird and wonderful physics found in leaves.

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf [0:00] Intro[2:10] The Evolution of AI in Drug Discovery[6:09] Current State and Future of AI in Biotech[11:15] Challenges and Modalities in Therapeutics[15:19] Data Generation and Model Training[23:59] Open Source and Model Development at Chai[28:35] Protein Structure Prediction and Diffusion Models[30:57] Open Source Models and Their Impact[35:41] How Should Chai-2 Be Used?[39:34] The Future of AI in Pharma and Biotech[43:51] Key Milestones and Metrics in AI-Driven Drug Discovery[48:24] Critiques and Hesitation[55:06] Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

George Congdon joins Morning Movers to look at an AI player in the healthcare space: Tempus AI (TEM). Shares of TEM have rallied higher after its 2Q earnings. George breaks down the latest results and the company's raised guidance. He says customers like AstraZeneca (AZN) like TEM's ability to provide data-driven insights that can potentially provide accelerated drug discovery.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the "gray areas" of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue analysis require more nuanced, fit-for-purpose approaches. A key theme is the need for flexibility and client collaboration, particularly when defining what constitutes validation versus qualification. The hosts emphasize how evolving technologies and commercially available reagents are enabling more streamlined, context-driven assays, though terminology differences—especially between U.S. and EU practices—continue to cause confusion. They close with a discussion on tissue assay limitations, particularly the inherent variability introduced during sample homogenization.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

Send us a textBill Taranto is President of the Merck Global Health Innovation Fund ( MGHIF - https://www.msdghifund.com/ ).The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck's core business of discovering, developing and marketing innovative drugs and vaccines.Bill has more than three decades of experience in the healthcare industry. MGHIF is a $750m evergreen fund focused on identifying opportunities that are adjacent to Merck's core business of pharmaceuticals and vaccines. Under Bill's leadership, MGHIF has invested more than $1bn in 70 companies, with more than $7bn in exits.Prior to joining Merck, Bill spent 18 years at Johnson & Johnson (J&J) in various roles. As VP of healthcare strategy and venture at J&J, he was responsible for evaluating and creating new healthcare business models through venture capital and acquisitions. Prior to joining J&J, Bill spent eight years in investment banking.#BillTaranto #MerckGlobalHealthInnovationFund #Scale #Impact #InvestmentBanking #DrugDiscovery #ClinicalDevelopment #Manufacturing #SupplyChain #RealWorldEvidence #CorporateVentureCapital #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

In this episode of Tech Bytes, host Dan Hafner delves into the Trump administration's ambitious AI action plan aimed at securing US global leadership. Discover how this comprehensive strategy seeks to accelerate innovation, expand AI infrastructure, and enhance international leadership, all while addressing regulatory challenges and prioritizing AI education. Join us as we explore the implications of this bold move and its potential to reshape the global AI landscape. Tune in for an insightful discussion on the future of AI and its role in maintaining US economic and military superiority. #AI #USLeadership #Innovation

Want the ultimate guide to Google's Gemini? Get it here: https://clickhubspot.com/evt Episode 68: How is Google DeepMind pushing the boundaries of AI to tackle drug discovery, robotics, and even autonomous AI agents? Matt Wolfe (https://x.com/mreflow) sits down with DeepMind CEO Sir Demis Hassabis (https://x.com/demishassabis), a neuroscientist, AI pioneer, Nobel laureate, and knight, to peel back the curtain on Google's latest advances—and the ethical challenges that come with them. In this episode, Matt and Demis go deep on what's powering the newest generation of AI agents, how models like AlphaFold and AlphaEvolve are accelerating scientific breakthroughs, and why world models are so important for the future of robotics. Demis shares why he believes AI is poised to reshape society—for better and for worse—and what Google is doing to build public trust in its systems. Check out The Next Wave YouTube Channel if you want to see Matt and Nathan on screen: https://lnk.to/thenextwavepd — Show Notes: (00:00) AI Revolutionizing Drug Discovery (03:35) Advanced Model Training Methods (07:06) Accelerating Drug Discovery with AI (11:12) AI's Responsible Role in Society (13:56) AI Revolutionizing Science & Life — Mentions: Sir Demis Hassabis: https://www.linkedin.com/in/demishassabis/ Google DeepMind: https://deepmind.google/ AlphaFold: https://alphafold.ebi.ac.uk/ AlphaEvolve: https://deepmind.google/discover/blog/alphaevolve-a-gemini-powered-coding-agent-for-designing-advanced-algorithms/ Isomorphic Labs: https://www.isomorphiclabs.com/ Android XR glasses: http://blog.google/products/android/android-xr-gemini-glasses-headsets/ Get the guide to build your own Custom GPT: https://clickhubspot.com/tnw — Check Out Matt's Stuff: • Future Tools - https://futuretools.beehiiv.com/ • Blog - https://www.mattwolfe.com/ • YouTube- https://www.youtube.com/@mreflow — Check Out Nathan's Stuff: Newsletter: https://news.lore.com/ Blog - https://lore.com/ The Next Wave is a HubSpot Original Podcast // Brought to you by Hubspot Media // Production by Darren Clarke // Editing by Ezra Bakker Trupiano

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody discovery with AI”.  In the first article, Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. In the second article, DDW Editor Reece Armstrong, speaks to Kashif Sadiq, Founder of DenovAI Biotech about the importance of computational methods in this field.

Synopsis: What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents. Biography: Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company's mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases. Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company's Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris' legal and intellectual property functions, including licensing, corporate governance, and management of the company's global patent portfolio. Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP. Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master's in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law.

AI has already fueled breakthroughs in biotechnology—but now, further advances in AI are poised to fuel pharmaceutical discoveries as well. Sarah Guo sits down with Joshua Meier and Jack Dent, co-founders of Chai Discovery, whose newly launched Chai-2 designs bespoke antibodies that bind to their targets at a jaw-dropping 20% rate. Jack and Joshua talk about the implications for Chai-2's success rate at discovering antibodies for the pharmaceutical industry, how structure prediction is pivotal in making the model work, and future potential for using the model to optimize other molecular properties. Plus, they talk about what they believe bioscientists should be learning to best utilize Chai-2's technology.  Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @_jackdent | @joshim5 Chapters: 00:00 – Joshua Meier and Jack Dent Introduction 01:09 – Genesis of Chai Discovery 06:12 – Chai-2 Model 10:13 – Criteria for Specifying Targets for Chai-2 13:12 – How the Chai-2 Model Works 16:12 – Emergent Vocabulary from Chai-2 18:15 – Hopes for Chai-2's Impact 20:33 – Reception of the Chai-2 Model 22:16 – Future of Wet Lab Screening and Biotech 27:08 – Optimizing Other Molecule Properties 31:37 – Where Chai Invests From Here 36:20 – What Bioscientists Should Learn for Chai-2 40:23 – How Jack and Josh Oriented to the Biotech Space 43:38 – Platform Investment and Chai-2 46:53 – Scaling Chai Discovery 48:21 – Hiring at Chai Discovery 49:09 – Conclusion

What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.⁠⁠TPM E47 highlights >⁠⁠⁠⁠⁠⁠⁠⁠Episode 47 links:Archetype TherapeuticsTom Neyarapally on LinkedIn “Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten

Today's guest is Annabel Romero, Specialist Leader focusing on AI for Drug Discovery at Deloitte and a structural biologist by training. Deloitte is a global consulting firm known for its work in digital transformation, data strategy, and AI adoption across regulated industries. Annabel joins Emerj Editorial Director Matthew DeMello to explore how AI systems are being designed to think more like scientists—particularly in protein modeling and life sciences research. She shares how tools like AlphaFold and large language models are accelerating drug targeting, predicting allergen cross-reactivity, and translating learnings from human biology to agricultural innovation. This episode is sponsored by Deloitte. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

In this episode of Breaking Health, host Steve Krupa speaks with Matt Bettonville, investor at Yosemite, about the state of oncology research and his hunt for investments in discovery and treatment tools. Bettonville delves into the key to cancer treatment, where deals are flowing towards in the market, and how the AI revolution is helping with drug discovery and cancer treatment breakthroughs. He also discusses the complications (and frustrations) of making treatments affordable, finding new targets in primary cancers most frequently seen in the population, and the importance of early detection. Links from this episode:  HealthEdgeYosemite  

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of drug discovery”, and “The era of precision neuroscience”. In the first article, Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need. In the second article, James Peach, Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process, shares insight with me.  In the third article, Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments for neurological and neuropsychiatric diseases.

On today's show we're excited to welcome Rick Peng, the Innovation Hub Manager and Digital Licensing Professional at Memorial Sloan Kettering Cancer Center. We talk about how your organization can build an outside-in, external innovation program to deliver outsized results. Rick breaks down the secret sauce of the MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients. We discuss their new Innovation Hub Challenge focused on AI Drug Discovery – and why the access to data sets, is a key unlock for ai driven solutions.

Zach Weinberg, co-founder and CEO of Curie.Bio, is redefining early-stage biotech investing with an operator's mindset and a founder-first philosophy. His approach combines funding with operational support and direct access to world-class drug hunters to dramatically increase odds of success. Today, Zach sits down with Nick Chirls, GP at Asylum Ventures and Beezer Clarkson,  LP at Sapphire Partners to discuss the massive risk associated with traditional therapeutics startups, how pairing a drug discovery partner with a seed investor solves those inefficiencies, and how biotech, the global economy and the political landscape are all closely connected.Learn more about Sapphire Partners: sapphireventures.com/sapphire-partnersLearn more about OpenLP: openlp.vcLearn more about Asylum Ventures: asylum.vcLearn more about Curie.Bio: curie.bioFor a monthly roundup of the latest venture insights, including the newest Origins episodes, subscribe to the OpenLP newsletter – delivered straight to your inbox: subscribe.openlp.vcCHAPTERS:(0:00) Welcome to Origins(5:08) Was Hunter High School Harder Than Penn?(10:22) Transitioning From SaaS to Biotech(20:55) Why Is Building a Biotech Venture Firm So Hard?(27:55) Building Curie.Bio(32:24) Zach on Drug Discovery(43:12) Biotech in China(49:42) AI in Biotech(54:51) "The Manhattan Project of Biology"

In our next episode, we're joined by Jason Cole, a Senior Research Fellow at the Cambridge Crystallographic Data Center (CCDC). He shares his fascinating journey, starting from his childhood in Italy, where his love for science blossomed, all the way to his impressive career in computational chemistry and crystallography. We chat about what CCDC does in terms of gathering and sharing crystallographic data, the ups and downs of software development in this field, and why it's so crucial to validate docking software. Jason also highlights the importance of data standards, the philanthropic mission of CCDC, and what the future holds for drug discovery, particularly with the exciting possibilities of artificial intelligence (AI) and quantum computing. It's a great conversation packed with insights!

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women's health” and “Could NfL accelerate drug development for neurodegenerative diseases?” In the first article, DDW Editor Reece Armstrong speaks to Dr Steve Gardner, Co-Founder and CEO of PrecisionLife about work the company is doing to improve our understanding of endometriosis. In the second article, Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases.

Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-167-with-tom-sakmar-%26-ilana-kotliar---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Simply Wall St Market Insights for the week ending 25th May 2025.To read the full article:

Welcome back to Impact Theory with Tom Bilyeu. In this episode, I sit down with my co-host Drew to rip into one of the most turbulent weeks in global politics and economics we've seen in a long time. We break down not just the moves, but the motives and the possible massive consequences behind Trump's high-octane foreign policy—from slashing tariffs with China and locking in a colossal Saudi investment deal, to taking the unprecedented step of targeting Big Pharma with an executive order to lower drug prices. We get into whether all this fast action is actually helping America or just stirring up more chaos. Are we leveraging our moment, or just getting played by the likes of Xi and Putin? Does tough talk and bold negotiating end with real results for America, or are we setting ourselves up for long-term headaches, especially with midterms on the horizon? Then we peel back the layers on some of the rawest culture war issues, from immigration crackdowns in the UK, the controversy about a Muslim-majority city in Texas, to the viral video of world leaders acting out-of-pocket on a train to Kiev. SHOWNOTES 00:00 – China's 90-Day Tariff Pause: Progress or a Lifeline for Xi? 01:42 – Negotiation Tactics: Deal-Making or Getting Played? 03:48 – The Real Purpose of the 90-Day Pause 05:16 – China Can Print Money: Central Banks and Sinister Power 07:13 – Trump's Aggressive Approach: Productive Chaos? 09:14 – What's Actually Getting Done—And What's Just PR? 10:57 – Accepting a Gold-Plated Jet: Smart Move or Trojan Horse? 13:29 – Why “Greedy Capitalist” Isn't Always an Insult 15:51 – When Deals Cross the Line 18:38 – Global Trade Rebalancing: Is Win-Win Possible with China? 21:17 – Breaking Down the $600 Billion Saudi Deal 24:23 – Why Innovation Stalled—and What Competition With China Could Spark 25:54 – Instilling Inspiration vs. Self-Loathing in American Youth 29:31 – Price Fixing Big Pharma: Popular, but Ultimately Dangerous? 32:15 – Central Banks: The Fungus Beneath the Free Market 36:07 – How Drug Pricing Actually Gets Decided (and Where It Breaks Down) 39:04 – Why Price Fixing Backfires 42:36 – Cigarettes, Prisons, and the True Nature of Supply & Demand 47:14 – Drug Discovery, Innovation, and Unintended Consequences 54:58 – Culture Wars: Immigration Policy in the UK and the US 58:34 – Building the Modern Middle East—Without Western Intervention 60:48 – The Harsh Realities of Assimilation and Cultural Conflict 65:35 – What Happens When Zoning and Religion Collide? 71:19 – Demographics as Destiny: What History Teaches About Outnumbering 74:00 – Respecting Law, Freedom, and What It Means to Be American CHECK OUT OUR SPONSORS ButcherBox: Ready to level up your meals? Go to ⁠https://ButcherBox.com/impact⁠ to get $20 off your first box and FREE bacon for life with the Bilyeu Box! Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Shopify: Sign up for your one-dollar-per-month trial period at ⁠https://shopify.com/impact⁠ Netsuite: Download the CFO's Guide to AI and Machine Learning at ⁠https://NetSuite.com/THEORY⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at ⁠https://mintmobile.com/impact.⁠  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. Learn more about your ad choices. Visit megaphone.fm/adchoices

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

Unlock faster, smarter drug repurposing with open-source data that arms clinicians and researchers with actionable insights. This discussion explores how cutting-edge AI and knowledge graphs are transforming access to potential therapies by ranking 4,000 approved drugs against thousands of diseases - all in record time. Host Dr. Sanjay Juneja speaks with Dr. David Fajgenbaum, Co-founder of Every Cure, to reveal how their platform delivers 75 million computed drug-disease scores directly into the hands of healthcare providers worldwide. Learn how this approach accelerates clinical decision-making, supports evidence-based research, and breaks down barriers to innovative care strategies.

What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines. With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTsAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here

"I was born and raised in a developing country. I was born and raised in Pakistan. And it's very interesting when you're born in a developing country. That's your world. Right? That's all you know." In this episode of The Biotech Startups Podcast, we delve into Rabia Khan's remarkable journey from her childhood in Pakistan to founding Serna Bio, an AI-enabled drug discovery company. Rabia shares how her early experiences in a developing country, her aunt's battle with schizophrenia, and the sequencing of the human genome in 2000 sparked her passion for genetics and healthcare. She recounts how her career options were either medicine or engineering, setting her on a path that would eventually lead to pioneering work at the intersection of AI and biotechnology. Rabia describes her transition to McGill University in Montreal, facing the shock of -40°C weather with only a leather jacket while navigating life as an international student with no support system. Despite these challenges, she pursued dual interests in biology and economics, finding her first research opportunity in a schizophrenia lab where she started by pipetting water and washing dishes.

In this episode of Crazy Wisdom, Stewart Alsop speaks with German Jurado about the strange loop between computation and biology, the emergence of reasoning in AI models, and what it means to "stand on the shoulders" of evolutionary systems. They talk about CRISPR not just as a gene-editing tool, but as a memory architecture encoded in bacterial immunity; they question whether LLMs are reasoning or just mimicking it; and they explore how scientists navigate the unknown with a kind of embodied intuition. For more about German's work, you can connect with him through email at germanjurado7@gmail.com.Check out this GPT we trained on the conversation!Timestamps00:00 - Stewart introduces German Jurado and opens with a reflection on how biology intersects with multiple disciplines—physics, chemistry, computation.05:00 - They explore the nature of life's interaction with matter, touching on how biology is about the interface between organic systems and the material world.10:00 - German explains how bioinformatics emerged to handle the complexity of modern biology, especially in genomics, and how it spans structural biology, systems biology, and more.15:00 - Introduction of AI into the scientific process—how models are being used in drug discovery and to represent biological processes with increasing fidelity.20:00 - Stewart and German talk about using LLMs like GPT to read and interpret dense scientific literature, changing the pace and style of research.25:00 - The conversation turns to societal implications—how these tools might influence institutions, and the decentralization of expertise.30:00 - Competitive dynamics between AI labs, the scaling of context windows, and speculation on where the frontier is heading.35:00 - Stewart reflects on English as the dominant language of science and the implications for access and translation of knowledge.40:00 - Historical thread: they discuss the Republic of Letters, how the structure of knowledge-sharing has evolved, and what AI might do to that structure.45:00 - Wrap-up thoughts on reasoning, intuition, and the idea of scientists as co-evolving participants in both natural and artificial systems.50:00 - Final reflections and thank-yous, German shares where to find more of his thinking, and Stewart closes the loop on the conversation.Key InsightsCRISPR as a memory system – Rather than viewing CRISPR solely as a gene-editing tool, German Jurado frames it as a memory architecture—an evolved mechanism through which bacteria store fragments of viral DNA as a kind of immune memory. This perspective shifts CRISPR into a broader conceptual space, where memory is not just cognitive but deeply biological.AI models as pattern recognizers, not yet reasoners – While large language models can mimic reasoning impressively, Jurado suggests they primarily excel at statistical pattern matching. The distinction between reasoning and simulation becomes central, raising the question: are these systems truly thinking, or just very good at appearing to?The loop between computation and biology – One of the core themes is the strange feedback loop where biology inspires computational models (like neural networks), and those models in turn are used to probe and understand biological systems. It's a recursive relationship that's accelerating scientific insight but also complicating our definitions of intelligence and understanding.Scientific discovery as embodied and intuitive – Jurado highlights that real science often begins in the gut, in a kind of embodied intuition before it becomes formalized. This challenges the myth of science as purely rational or step-by-step and instead suggests that hunches, sensory experience, and emotional resonance play a crucial role.Proteins as computational objects – Proteins aren't just biochemical entities—they're shaped by information. Their structure, function, and folding dynamics can be seen as computations, and tools like AlphaFold are beginning to unpack that informational complexity in ways that blur the line between physics and code.Human alignment is messier than AI alignment – While AI alignment gets a lot of attention, Jurado points out that human alignment—between scientists, institutions, and across cultures—is historically chaotic. This reframes the AI alignment debate in a broader evolutionary and historical context, questioning whether we're holding machines to stricter standards than ourselves.Standing on the shoulders of evolutionary processes – Evolution is not just a backdrop but an active epistemic force. Jurado sees scientists as participants in a much older system of experimentation and iteration—evolution itself. In this view, we're not just designing models; we're being shaped by them, in a co-evolution of tools and understanding.

Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages.  By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease."    "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker."  #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers  sapient.bio Download the transcript here

Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages.  By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease."    "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker."  #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers  sapient.bio Listen to the podcast here

OpenAI has successfully raised $40 billion in what is believed to be the largest private technology funding round ever, boosting its valuation to $300 billion. This funding round was predominantly led by the Japanese investment firm SoftBank, which has now surpassed Microsoft as OpenAI's largest investor. Despite the impressive growth in revenue and user base, OpenAI continues to face challenges in achieving profitability, as it invests heavily in infrastructure and user acquisition. The company has announced plans to release its first open-weight language model since 2019, marking a strategic shift to adapt to competitive pressures from open-source alternatives.The podcast also highlights significant advancements in AI applications across various sectors. Researchers are leveraging AI to accelerate drug repurposing, enabling faster exploration of treatment options for patients with limited choices. American Express has integrated AI into its internal IT support, achieving a remarkable reduction in IT escalations and enhancing travel assistance for its elite customers. These examples illustrate the potential of AI to deliver tangible business value and improve operational efficiency.However, the integration of AI is not without its challenges. Bloomberg News has faced difficulties in generating accurate AI summaries for articles, leading to corrections and concerns about the reliability of AI-generated content. This underscores the importance of maintaining quality control and human oversight in AI applications, particularly in fields like journalism where accuracy is paramount.The episode concludes with a discussion on trends towards simplifying complex processes in business. Innovations such as rapid business valuation tools, enhanced customer communication through Rich Communication Services, and streamlined cyber insurance solutions reflect a broader movement to improve efficiency and accessibility in various industries. These developments highlight the ongoing evolution of technology and its impact on business operations, emphasizing the need for strategic implementation of AI and other technological advancements. Three things to know today 00:00 OpenAI's Rollercoaster Ride: Big Money, Open Models, and Profit Puzzles06:29 AI Wins and Woes: Curing Disease, Solving Problems, and Sometimes Missing the Mark10:41 MSPs Get a Boost: Faster Insights, Smoother Communication, and Insurance Made Easy  Supported by:  https://getnerdio.com/nerdio-manager-for-msp/  Join Dave April 22nd to learn about Marketing in the AI Era.  Signup here:  https://hubs.la/Q03dwWqg0 All our Sponsors: https://businessof.tech/sponsors/ Do you want the show on your podcast app or the written versions of the stories? Subscribe to the Business of Tech: https://www.businessof.tech/subscribe/Looking for a link from the stories? The entire script of the show, with links to articles, are posted in each story on https://www.businessof.tech/ Support the show on Patreon: https://patreon.com/mspradio/ Want to be a guest on Business of Tech: Daily 10-Minute IT Services Insights? Send Dave Sobel a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/businessoftech Want our stuff? Cool Merch? Wear “Why Do We Care?” - Visit https://mspradio.myspreadshop.com Follow us on:LinkedIn: https://www.linkedin.com/company/28908079/YouTube: https://youtube.com/mspradio/Facebook: https://www.facebook.com/mspradionews/Instagram: https://www.instagram.com/mspradio/TikTok: https://www.tiktok.com/@businessoftechBluesky: https://bsky.app/profile/businessof.tech

How is the pharmaceutical industry evolving to meet the world's biggest health challenges? In this episode, Nicolai Tangen sits down with Emma Walmsley, CEO of GSK, for an insightful conversation about the future of pharmaceuticals. They discuss GSK's latest advances in cancer treatments, HIV therapies, and respiratory medicine, as well as the role of AI in speeding up drug discovery. Emma also shares her thoughts on navigating change, transforming company culture, and the role of curiosity in staying motivated. Tune in!In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

Synopsis: How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture. Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify's groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies. He also dives deep into biotech innovation, smart capital strategy, M&A trends, and the power of hiring the right talent. Whether you're a biotech founder, investor, or science enthusiast, this episode is packed with insights on building, funding, and scaling a biotech startup in today's competitive landscape. Biography: Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify Pharma and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development, and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from the University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss his groundbreaking work in drug discovery using artificial intelligence. Dr. Gupta shares insights from his career, including his leadership in combating the opioid crisis, and explains how AI and machine learning are transforming the speed, cost, and success rates of drug development.

The future of medicine is being shaped by technology, and few companies are pushing the boundaries like GSK. In this episode, I sit down with Christopher Austin, Head of Research Technologies at GSK, to explore how AI, data science, and cutting-edge digital capabilities are revolutionizing drug discovery and development. Chris shares how GSK is harnessing vast datasets, AI-driven insights, and genetic validation to speed up the identification of promising drug targets. We discuss how computational biology and machine learning are dramatically reducing the time it takes to develop new treatments—sometimes cutting discovery timelines in half. From selecting the right molecular designs to improving patient identification for clinical trials, technology is streamlining the entire R&D process, increasing success rates, and ultimately bringing life-saving medicines to patients faster. We also dive into the role of generative AI in modeling diseases, designing antibodies, and optimizing clinical trials. With AI now shaping everything from drug formulation to patient recruitment, we explore what this means for the future of medicine and the ethical considerations that come with such rapid advancements. How will AI-driven drug discovery change the pharmaceutical industry in the next decade? What challenges remain in integrating these new technologies into traditional research models? And what does all of this mean for patients and the future of healthcare? Tune in to hear how GSK is leading the charge in transforming medicine through technology.

Today's guest is Liran Belenzon, Co-founder and CEO of BenchSci. BenchSci is a global leader in AI solutions for preclinical R&D that helps decipher complex biomedical research using proprietary technology. Liran joins us to discuss how AI is transforming disease biology research, streamlining scientific workflows, and enabling better decision-making in pharmaceutical R&D. Liran shares insights into the biggest challenges facing drug discovery today, including the complexity of disease biology and the critical role AI plays in unraveling it. He breaks down how AI-driven knowledge graphs, ontological models, and multimodal AI systems are improving both the speed and quality of scientific research. This episode is sponsored by BenchSci. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

A recent study in the journal Nature unveiled new proteins that can neutralize the deadliest of snake venoms. They're “new” in that they aren't found in nature—they were created in a lab, dreamed up by AI.Using AI to discover, or design, the building blocks of drugs is a fast-growing area of research. Another team of scientists out of Philadelphia is using AI to discover new antibiotics by resurrecting long-lost molecules from extinct species like neanderthals and woolly mammoths.We know what you're thinking: It sounds too sci-fi to be true.Flora Lichtman talks with two pioneers in the field about how AI is supercharging drug discovery: Dr. César de la Fuente, bioengineer and presidential associate professor at the University of Pennsylvania in Philadelphia, and Nobel laureate Dr. David Baker, director of the Institute for Protein Design and professor at the University of Washington in Seattle.Transcripts for each segment will be available after the show airs on sciencefriday.com.For our Los Angeles listeners: We're working on a story about the toxins left behind by the fires and we want to hear from you. How is this affecting you? Are you worried about the air and water and soil? How are you approaching clean-up? And what questions do you have?Leave us a voicemail at 1-646-767-6532 or send us an email at scifri@sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Plus, Open AI CEO Sam Altman is sued by his sister. And Meta tests eBay crossovers on Facebook Marketplace. James Rundle hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices